Therapeutic Index of Targeted Therapies and Conventional Cytotoxics
Grace Dy, MD, from the Roswell Park Cancer Institute, discusses the therapeutic index of targeted therapies and conventional cytotoxics.
Grace Dy, MD, Associate Professor, Department of Medicine, Roswell Park Cancer Institute, discusses the therapeutic index of targeted therapies and conventional cytotoxics.
As the oncology community has learned over time, the idea that the therapeutic index of targeted therapies as a group is much better than cytotoxics may not be entirely true. Certain toxicities such as myelosuppression or hair loss may not be as common in patients treated with targeted therapies.
Clinical Pearls
Targeted therapies have shown that they can affect multiple organs in the body as some drugs inhibit targets found in normal tissues. This causes an entire spectrum of side effects that are difficult to anticipate. Targeted therapies make treatment much more interesting and challenging for a medical oncologist, Dy says.
- The therapeutic index of targeted therapies as a group is not necessarily better than conventional cytotoxics
- The targets of these therapies may be found in normal tissues and therefore affect multiple organs
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
